“This early but promising observational study suggests a powerful synergy: patients with stage III colon cancer who embraced anti-inflammatory foods and exercised regularly showed the best overall ...

“This trial emphasizes the importance of germline and somatic testing in patients with metastatic prostate cancer at the time of diagnosis; homologous recombination repair mutations have been ...

“This is the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer to demonstrate that post-treatment exercise is both achievable and effective in improving ...

Main Takeaway Perioperative treatment with durvalumab (Imfinzi) and chemotherapy led to longer survival without cancer recurrence, progression or treatment-related complications for patients with ...

The Minnesota Society of Clinical Oncology (MSCO) is the recipient of the 2024 Jeffery C. Ward Affiliate Advocacy Award. The Association for Clinical Oncology presented the award during the State ...

“The findings from Destiny-Breast09 represent a new first line standard treatment option for HER-2 positive metastatic breast cancer. The duration of therapy can now be measured in years and gives us ...

“The early switch approach of the SERENA-6 clinical trial resulted in a 56% reduction in the risk of disease progression or death for patients who switched to treatment with camizestrant, allowing ...

“This study will change the standard of care for the subset of patients with deficient DNA mismatch repair colon cancer by incorporating atezolizumab to standard of care FOLFOX chemotherapy in the ...

Do you know someone who would make a good ASCO President, Board member, or Nominating Committee member? In advance of the upcoming election, the ASCO Nominating Committee is seeking recommendations ...

An internationally recognized oncology leader and health care executive, Dr. Knudsen is the CEO of the Parker Institute for Cancer Immunotherapy. Dr. Knudsen was previously CEO of the American Cancer ...

Disclaimer This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information ...

Who does this study affect? People with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer who develop a mutation in the estrogen receptor ...